SCHEDULE 14C INFORMATION
     Proxy Statement Pursuant to Section 14(c) of the Securities Act of 1934
                               (Amendment No. 1)


(Mark One)
Filed by the Registrant                              [X]
Filed by a Party other than the Registrant           [ ]

Check the appropriate box:
[X]  Preliminary Information Statement
[ ]  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
     (2))
[ ]  Definitive Information Statement
[ ]  Definitive Additional Materials

                              ENHANCE BIOTECH, INC.
                (Name of Registrant as Specified in Its Charter)
                 (Formerly known as BECOR COMMUNICATIONS, INC.)

Payment of Filing Fee (Check the appropriate box):
[X]  No fee required.
[ ]  Fee computed on the table below per Exchange Act Rules 14c-5(g) and 0-11.

     (a)  Title of each class of securities to which transaction applies:

          ---------------------------------------------------------------------
     (b)  Aggregate number of securities to which transaction applies:

          ---------------------------------------------------------------------

     (c)  Per unit  price  or other  underlying  value of  transaction  computed
          pursuant to Exchange  Act Rule 0-11 (set forth the amount on which the
          filings fee is calculated and state how it was determined):

          ---------------------------------------------------------------------

     (d)  Proposed maximum aggregate value of transaction:

          ---------------------------------------------------------------------

     (e)  Total fee paid:

          ---------------------------------------------------------------------

[ ]  Fee paid previously with preliminary materials.
[ ]  Check box if any part of the fee is offset as provided  by Exchange  Action
     Rule 0-11 (a) (2) and identify the filing for which the  offsetting fee was
     paid  previously.  Identify the previous filing by  registration  statement
     number, or the Form or Schedule and the date of its filing.
     1) Amount Previously Paid:
                               ------------------------------------------
     2) Form, Schedule or Registration Statement No.:
                                                     --------------------
     3) Filing Party:
                     ----------------------------------------------------
     4) Date Filed:
                   ------------------------------------------------------





THE FOLLOWING PARAGRAPH IS PROVIDED FOR EXPLANATION PURPOSES ONLY AND IS NOT AND
SHOULD  NOT BE  CONSIDERED  TO BE PART OF THE  PROXY  OR  INFORMATION  MATERIALS
FURNISHED BY ENHANCE  BIOTECH,  INC.  (FORMERLY  KNOWN AS BECOR  COMMUNICATIONS,
INC.) (THE "COMPANY").

THIS PRER 14C INFORMATION  STATEMENT IS INTENDED TO REVISE AND REPLACE THE PRIOR
SOLICITATION/INFORMATION  MATERIALS  FILED BY THE COMPANY ON FORM PRE 14A, FILED
ON FEBRUARY 20, 2003; FORM PRER 14A FILED ON FEBRUARY 21, 2003; AND FORM PRE 14C
FILED ON MARCH 7, 2003.





                              ENHANCE BIOTECH, INC.
                 (FORMERLY KNOWN AS BECOR COMMUNICATIONS, INC.)

             DEFINITIVE INFORMATION STATEMENT PURSUANT TO SECTION 14
       OF THE SECURITIES EXCHANGE ACT OF 1934 AND SCHEDULE 14C THEREUNDER
                              --------------------

                      WE ARE NOT ASKING YOU FOR A PROXY AND
                 YOU ARE NOT BEING REQUESTED TO SEND US A PROXY

                                  INTRODUCTION

         This information statement ("Information  Statement") will be mailed on
or about April 8, 2003, to the  shareholders  of record as of February 28, 2003,
of  Enhance  Biotech,  Inc.  a  Delaware  corporation  (formerly  known as Becor
Communications,  Inc.)(the  "Company")  in  connection  with action taken by the
Company pursuant to the written consent of a majority of the shareholders of the
Company on February 21, 2003 ("Written Consent").

         There will not be a meeting of stockholders  and none is required under
the Delaware  General  Corporation  Law because this action has been approved by
written  consent of the holders of a majority of the  outstanding  shares of our
voting common stock. Under Section 228 of the Delaware General  Corporation Law,
we are  required  to provide  prompt  notice of the taking of  corporate  action
without a  meeting  to our  stockholders  of record  who have not  consented  in
writing to this action.  This  Information  Statement is intended to provide you
with the required notice.

                 THIS IS NOT A NOTICE OF MEETING OF SHAREHOLDERS
                    AND NO SHAREHOLDERS' MEETING WILL BE HELD
                     TO CONSIDER ANY MATTER DESCRIBED HEREIN

                              ENHANCE BIOTECH, INC.
                 (Formerly known as BECOR COMMUNICATIONS, INC.)
                          17337 Ventura Blvd., Ste. 224
                            Encino, California 91316

             DEFINITIVE INFORMATION STATEMENT PURSUANT TO SECTION 14
       OF THE SECURITIES EXCHANGE ACT OF 1934 AND SCHEDULE 14C THEREUNDER

         To the stock holders of ENHANCE BIOTECH,  INC. (Formerly known as BECOR
COMMUNICATIONS, INC.):


                                        2





         NOTICE IS  HEREBY  GIVEN  that the  following  action  was taken by the
Company  pursuant to a Written  Consent of the Majority  Shareholders of Enhance
Biotech, Inc. (formerly known as Becor  Communications,  Inc.). The action taken
consists of:

         The amendment of the Company's  Certificate of  Incorporation to change
the name of the Company to "ENHANCE BIOTECH, INC."

         The  Certificate of Amendment was filed with the Delaware  Secretary of
State on March 25, 2003.

         The  Company  has asked  brokers  and other  custodians,  nominees  and
fiduciaries to forward this  Information  Statement to the beneficial  owners of
the  Common  Stock  of the  Company  held of  record  by such  persons  and will
reimburse such brokers and other custodians for out-of-pocket  expenses incurred
in forwarding such material. The Board of Directors has established the close of
business on February  28, 2003,  as the record date (the "Record  Date") for the
determination of stockholders entitled to notice of the action taken pursuant to
the Written Consent.

                                        By Order of the Board of Directors



                                        ------------------------------------
                                        Buddy Young, Chief Executive Officer
Encino, California
April 8, 2003

                               GENERAL INFORMATION
                               -------------------

PRIOR REVIEW

         Although copies of this  Information  Statement have been filed with an
examined by the Securities and Exchange Commission  ("Commission"),  such filing
and  examination by the Commission does not represent and shall not be deemed to
be a  finding  that the  materials  are  accurate  or  complete  or not false or
misleading.  Nor does it mean that the  Commission has passed upon the merits of
or approved any  statement  contained  in the  materials or any matter which was
taken by the Written Consent. No representation to the contrary has been made or
should be implied. Any representation to the contrary is a criminal offense.

NO FALSE OR MISLEADING STATEMENTS

         To the  best  of the  Company's  knowledge,  all  statements  made  and
contained herein are true at the time made and in the light of the circumstances
under which they are being made and are not false or misleading  with respect to
any material  fact or otherwise  omit any  material  fact  necessary to make the
statements herein not false or misleading or to correct any prior statements.


                                        3





ITEM 1 TO SCHEDULE 14C, INFORMATION REQUIRED BY SCHEDULE 14A
- ----------------------

ITEM 1 TO 14A, DATE, TIME AND PLACE INFORMATION

         (a) The date of the consent to the action  reported  was  February  21,
2003. The mailing address for the Company is 17337 Ventura Boulevard,  Suite 224
Encino, CA 91316.

         (b) This information statement ("Information Statement") will be mailed
on or about April 8, 2003,  to the  shareholders  of record as of  February  28,
2003, of the Company.

         (c) N/A

ITEM 2 TO 14A, REVOCABILITY OF PROXY                 N/A

ITEM 3 TO 14A, DISSENTER'S RIGHT OF APPRAISAL

         There are no appraisal rights regarding any matter to be acted upon.

ITEM 4 TO 14A, PERSONS MAKING SOLICITATION                    N/A

ITEM 5 TO 14A, INTERESTS OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON N/A

ITEM 6 TO 14A, VOTING SECURITIES AND PRINCIPAL HOLDERS THEREOF

         As of the close of business on February 28, 2003 (the  "Record  Date"),
the Company's authorized capitalization consisted of 25,000,000 shares of common
stock,  par value $.001 per share. As of the record date, there were One Million
Six Hundred Twelve Thousand Nine Hundred  (1,612,900)  shares of common stock of
the Company issued and outstanding, all of which were fully paid, non-assessable
and entitled to vote. Each share of common stock entitles its holder to one vote
on each mater submitted to the Shareholder.

         The  ownership  of the  Company's  Common  Stock by certain  beneficial
owners and by each of the Company's directors, named executive officers, and the
executive  officers  and  directors  as a group are  entitled to vote  1,270,000
shares of the  issued  and  outstanding  common  stock,  or 78.74% of the shares
entitled to vote.

ITEMS 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 & 18, TO 14A             N/A


                                        4





ITEM 19, AMENDMENT OF CHARTER, BYLAWS OR OTHER DOCUMENTS

         On February 21, 2003, the Company's  shareholders adopted a resolution,
among others, authorizing the Company's Board of Directors and Officers to amend
the Company 's Certificate of  Incorporation  (or charter)  changing the name of
the  Company  from  Becor  Communications,  Inc.  to  Enhance  Biotech,  Inc.  A
Certificate of Amendment to Certificate of Incorporation  changing the Company's
name to Enhance Biotech,  Inc. was filed with the Delaware Secretary of State on
March 25, 2003.

ITEM 20, 21 & 22           N/A

ITEM 2 TO SCHEDULE 14C, STATEMENT THAT PROXIES ARE NOT SOLICITED
- ----------------------

         We Are Not Asking You for a Proxy and You Are  Requested Not to Send Us
a Proxy.

ITEM 3 TO SCHEDULE 14C,  INTEREST OF CERTAIN PERSONS IN OR OPPOSITION TO MATTERS
- ----------------------
TO BE ACTED UPON

          The following  table sets forth  information  as of February 28, 2003,
regarding  beneficial  ownership  of the Common Stock of the Company by (i) each
person  known by the Company to be the  beneficial  owner of more than 5% of the
outstanding  shares of the  Company's  Common  Stock,  (ii) each director of the
Company,  (iii) the Chief Executive Officer and other executive  officers of the
Company and (iv) the  Company's  executive  officers  and  directors as a group.
Unless otherwise indicated,  the address of each stockholder listed in the table
is 17337 Ventura Boulevard, Suite 224, Encino, California 91316.

                                                                    PERCENTAGE
NAME AND ADDRESS                   NUMBER OF SHARES                  OWNERSHIP
- --------------------------------------------------------------------------------

Buddy and Rebecca Young(1)(2)          1,250,000                        77.55%
Howard Young (3)                          10,000                          *%
Dennis Spiegelman (4)                      5,000                          *%
L. Stephen Albright (5)                    5,000                          *%

All officers and directors
as a group (3 persons)                 1,270,000                       78.74%
* Less than 1%
- --------------------------------------------------------------------------------
(1) Held as co-trustees for the Young Family Trust.
(2) Mr. Young is a Director and the Chief Executive Officer of the Company.
(3) Howard Young is an officer and the son of Mr. Buddy Young.
(4) Director
(5) Director and Secretary


                                        5





ITEM 4 TO SCHEDULE 14C, PROPOSALS BY SECURITY HOLDERS
- ----------------------

         None of the Company's  security  holders has submitted any proposals to
the Company.

ITEM 5 TO SCHEDULE 14C,  DELIVERY OF  DOCUMENTS TO  SECURITY HOLDERS  SHARING AN
- ----------------------
ADDRESS

         Each security holder will be sent a copy of this Information Statement,
even if sharing an address with another security holder.

         The Company's  current office is 17337 Ventura Blvd., Ste. 224, Encino,
CA 91316. The phone number is (818) 784-0040.  Any security holder who wishes to
notify the  Company of that  security  holder's  desire to continue to receive a
separate Information  Statement or to receive a single Information  Statement at
an address  shared by multiple  security  holders may contact the Company at its
address and/or phone number with such request.


                                            By Order of the Board of Directors




                                            ------------------------------------
                                            BUDDY YOUNG, Chief Executive Officer

Encino, California
April 8, 2003


                                        6